GlobalData on MSN10h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trialShionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...
Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...
UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...
Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.
Dr. Gabriela Andujar Vazquez, with Dartmouth Health, is answering viewer questions as winter illnesses continue to spread.
"This 'quad-demic' is sort of this really tweetable term for our normal winter viruses: flu covid and RSV; and then a little bit of a wild card this year, we're seeing some higher numbers than usual ...
The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback